Fresenius Medical Care AG (NYSE:FMS) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC increased its holdings in shares of Fresenius Medical Care AG (NYSE:FMS) by 3,237.7% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 239,115 shares of the company’s stock after purchasing an additional 231,951 shares during the quarter. GAMMA Investing LLC’s holdings in Fresenius Medical Care were worth $5,954,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Smartleaf Asset Management LLC boosted its stake in shares of Fresenius Medical Care by 192.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after purchasing an additional 806 shares during the period. Russell Investments Group Ltd. boosted its stake in Fresenius Medical Care by 234.1% during the 4th quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company’s stock valued at $71,000 after acquiring an additional 2,208 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in Fresenius Medical Care by 80.5% during the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock valued at $102,000 after acquiring an additional 2,012 shares during the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Fresenius Medical Care by 8.4% during the fourth quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company’s stock worth $129,000 after purchasing an additional 441 shares during the period. Finally, Assetmark Inc. raised its holdings in shares of Fresenius Medical Care by 196.3% during the fourth quarter. Assetmark Inc. now owns 7,210 shares of the company’s stock worth $163,000 after purchasing an additional 4,777 shares during the period. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $28.60 on Tuesday. Fresenius Medical Care AG has a twelve month low of $17.93 and a twelve month high of $30.46. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The company has a 50-day moving average of $26.43 and a 200-day moving average of $24.58. The firm has a market cap of $16.79 billion, a price-to-earnings ratio of 23.64, a price-to-earnings-growth ratio of 0.76 and a beta of 0.88.

Fresenius Medical Care (NYSE:FMS) last announced its earnings results on Tuesday, May 6th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.43 by $0.01. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The company had revenue of $5.54 billion during the quarter, compared to analysts’ expectations of $4.71 billion. Analysts forecast that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The business also recently declared an annual dividend, which was paid on Friday, June 6th. Investors of record on Friday, May 23rd were issued a dividend of $0.7871 per share. This is a boost from Fresenius Medical Care’s previous annual dividend of $0.44. This represents a dividend yield of 1.9%. The ex-dividend date of this dividend was Friday, May 23rd. Fresenius Medical Care’s dividend payout ratio (DPR) is currently 50.89%.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Truist Financial increased their target price on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Monday, May 12th. Wall Street Zen started coverage on shares of Fresenius Medical Care in a report on Tuesday, May 20th. They issued a “strong-buy” rating on the stock. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care in a report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $27.80.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.